Cancer Biology & Medicine

►►Submit your paper by clicking the ABOVE RED TAG "ONLINE SUBMISSION".

 

►►Very important notification on publication fee

Effective February 2019, Cancer Biology & Medicine, as an open access journal, will charge a reasonable publication fee of $1,500/¥10,000 for each accepted article (all article types). No fees will be charged for invited articles.


Cancer Biology & Medicine

Cancer Biology & Medicine is a peer-reviewed open-access journal published by the China Anti-cancer Association (CACA), which is the leading professional society of oncology in China. Published quarterly, the journal provides innovative and significant information on the biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics:

● Cancer genetics

● Cancer and stem cell biology

● Molecular and clinical immunology

● Cancer prevention and epidemiology

● Cancer biomarkers

● Radiation oncology

● Oncology clinical trials

● Mechanisms of drug sensitivity and resistance

● Targeted therapy and immunotherapy

● Multidisciplinary treatment and personalized medicine

Author Benefits

● Easy submission via online system

● Efficient and professional peer review

● Rapid pre-print online publication

● No charge for publication and open access

● International visibility-All full texts are free in PubMed Central

 

Announcements

 

Publication of the 4th issue in 2020

 

In this issue, Prof. Wanqing Chen reviewed trends of cancer burden and risk factors in China. Prof. Junjie Chen’s review elucidated biological and clinical characteristics of HPV-related cancers. Besides, reviews about basic researches focus on cancer evolution and tumor microenvironment.

Original studies included new findings on mechanism of tumorigenesis and cancer development as well as novel discoveries in diagnosis and treatment for hepatocellular carcinoma, breast cancer, gastric cancer, and so on. We hope this issue will greatly benefit your research and clinical practice. Welcome to submit your work to Cancer Biology & Medicine.

 
Posted: 2020-11-11
 

Publication of the 3rd issue in 2020

 

As a global public health event, coronavirus disease (COVID-19) pandemic affects people’s health and routine life severely this year. For cancer patients with COVID-19, it’s very important to study their risks, clinical features, therapeutics, medical cares, and so on. In this issue, Prof. Xiaoping Miao and Xiaojiang Cui contribute an editorial and a review on this topic, respectively.

Several papers on basic researches focus the roles of some molecules in the tumorigenesis and cancer development, such as CMTM family proteins, Anoctamin 7 (ANO7), PRAS40, and SHP2. What’s more, reviews and original researches on clinical oncology would be attractive as well to readers. The contents refer to management strategy for papillary thyroid microcarcinoma, immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients, and outcomes of patients treated with SVILE vs. P-GemOx for extranodal natural killer/T-cell lymphoma, nasal type.

We hope this issue will greatly benefit your research and clinical practice. Welcome to submit your work to Cancer Biology & Medicine.

 
Posted: 2020-08-14
 
More Announcements...

Vol 17, No 4: November 2020

Table of Contents

Review

Evolving insights: how DNA repair pathways impact cancer evolution PDF HTML
Jiadong Zhou, et al. 805-827
Emerging data supporting stromal cell therapeutic potential in cancer: reprogramming stromal cells of the tumor microenvironment for anti-cancer effects PDF HTML
Armel H. Nwabo Kamdje, et al. 828-841
Adaptive response of resistant cancer cells to chemotherapy PDF HTML
Yi-Jye Chern, et al. 842-863
Biological and clinical aspects of HPV-related cancers PDF HTML
Klaudia Anna Szymonowicz, et al. 864-878
Cancer burden in China: trends, risk factors and prevention PDF HTML
Dianqin Sun, et al. 879-895
Current management of chemotherapy-induced neutropenia in adults: key points and new challenges PDF HTML
Yi Ba, et al. 896-909
Radiotherapy in combination with systemic therapies for brain metastases: current status and progress PDF HTML
Lei Liu, et al. 910-922
Exhausted T cells and epigenetic status PDF HTML
Ziqing Zeng, et al. 923-936

Original Article

The m6A methylation landscape stratifies hepatocellular carcinoma into 3 subtypes with distinct metabolic characteristics PDF HTML
Xiaotian Shen, et al. 937-952
Coordinated silencing of the Sp1-mediated long noncoding RNA MEG3 by EZH2 and HDAC3 as a prognostic factor in pancreatic ductal adenocarcinoma PDF HTML
Ting Han, et al. 953-969
Role of chromosomal instability and clonal heterogeneity in the therapy response of breast cancer cell lines PDF HTML
Natalia Vargas-Rondón, et al. 970-985
HM30181A, a potent P-glycoprotein inhibitor, potentiates the absorption and in vivo antitumor efficacy of paclitaxel in an orthotopic brain tumor model PDF HTML
Wu Zeng, et al. 986-1001
The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer PDF HTML
Yue Fan, et al. 1002-1013
Drug resistance gene expression and chemotherapy sensitivity detection in Chinese women with different molecular subtypes of breast cancer PDF HTML
Jing Zhao, et al. 1014-1025
Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers PDF HTML
Ying Cheng, et al. 1026-1038


OUR FRIENDS